The global transdermal drug delivery system market is expected to reach USD 81.4 billion by 2024, according to a new report by Grand View Research, Inc. The unprecedented global shift in the adoption of unhealthy lifestyles is presumed to be responsible for the high prevalence of chronic diseases, such as cancer and diabetes, which is expected to drive the clinical urgency to incorporate transdermal drug delivery systems in the future treatments. Moreover, the rising geriatric population base, which is highly susceptible to developing the aforementioned chronic diseases are expected to propel the demand for highly efficacious pharmacological drugs.
The market is driven by technological advancements in transdermal drug delivery devices, which is anticipated to serve the market with future growth opportunities. These advancements include advanced, third-generation, transdermal drug delivery technologies including iontophoresis, ultrasound, and microneedles or mechanical arrays. These technologies serve as effective transdermal drug diffusion alternatives that are capable of improving overall patient health and quality of life. For instance, the advent of matrix-controlled transdermal drug diffusion comprising a drug reservoir and a thermo effector, enhances skin permeation and enables controlled drug delivery.
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/transdermal-drug-delivery-systems-industry
Further key findings from the study suggest:
·
The cardiovascular application segment is
expected to exhibit growth at a significant CAGR of over 12.0% during the
forecast period. This is a consequence of the high clinical urgency to curb
hypertension and the need for precise drug delivery at a constant rate, which
has led to the development of transdermal drug delivery systems.
·
The mechanical array in the technology segment
is anticipated to witness an exponential CAGR of over 12.5%. The lucrative
growth is attributed to the availability of different forms of microneedle
transdermal systems, such as solid, hollow, and dissolving microneedles, as per
the suitability and needs of the patients.
·
In 2015, North America dominated the overall
Transdermal Drug Delivery System Market at over 50.0%. The consistent number of
product launches being undertaken and the continual participation of the
prominent players in conducting clinical trials are anticipated to promote the
incorporation of transdermal drug delivery systems.
·
The key players are increasingly involved in
initiating collaborative strategies and frequent product launches to capture a
larger market share. For instance, in September 2014, Noven Pharmaceuticals,
Inc. received the FDA approval for Minivelle, estradiol transdermal system to
be used for the prevention of postmenopausal osteoporosis. Furthermore, in June
2015, Boehringer Ingelheim GmbH sponsored the clinical trials, which
investigated the bioequivalence of transdermal clonidine administration.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices
Grand View Research has segmented the Transdermal Drug Delivery System
Market on the basis of technology, application, and region: Global Transdermal Drug Delivery Systems Product Outlook (Revenue, USD Billion, 2013 - 2024)
·
Electroporation
·
Radiofrequency
·
Iontophoresis
·
Microporation
·
Thermal
·
Mechanical arrays
·
Ultrasound
·
Others
Global Transdermal Drug Delivery Systems Application Outlook
(Revenue, USD Billion, 2013 - 2024)
·
Central nervous system
·
Pain management
·
Cardiovascular
·
Hormone
·
Others
Transdermal Drug Delivery Systems Regional Outlook (Revenue, USD
Billion, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
o
India
·
Latin America
o
Mexico
o
Brazil
·
MEA
o
South Africa
For press release of this report - http://www.grandviewresearch.com/press-release/global-transdermal-drug-delivery-system-market
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment